IP Library Granted Patent US 9,693,950
Granted Patent B2
US 9,693,950 · App. 13/699,805 · Granted Jul 4, 2017

Aqueous formulations for coating microneedle arrays

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,693,950
App. No.
13/699,805
Granted
Jul 4, 2017
Kind
B2
Abstract

Aqueous formulations that include at least one active pharmaceutical ingredient; and at least one excipient, wherein the aqueous formulation has a viscosity of from 500 to 30,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.; a surface tension that is not greater than 60 dynes/cm when measured under ambient conditions; or a contact angle on a medical grade polymeric material of 50° or greater when measured under ambient conditions. Methods of coating and coated microneedle arrays using the aqueous formulations are also disclosed herein.

Claims (31)

1. A method of forming a coated microneedle array comprising providing a microneedle array comprising a microneedle substrate and a plurality of microneedles;

providing a coating substrate;

providing an aqueous formulation comprising at least one active pharmaceutical ingredient and at least one excipient, wherein the aqueous formulation has a viscosity of from 500 to 30,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.;

applying the aqueous formulation to the coating substrate;

bringing the aqueous formulation and the microneedles of the microneedle array into contact with one another;

removing the microneedles from the aqueous formulation; and

allowing at least a portion of the aqueous formulation to evaporate,

wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 50° or greater and 96° or less when measured under ambient conditions.

2. The method according to claim 1 , wherein the viscosity is from 500 to 10,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.

3. The method according to claim 1 , wherein the viscosity is from 500 to 8,000 centipoise when measured at a shear rate of 100 s −1 and a temperature of 25° C.

4. The method according to claim 1 , wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 65° or greater and 96° C. or less when measured under ambient conditions.

5. A method of forming a coated microneedle array comprising

providing a microneedle array comprising a microneedle substrate and a plurality of microneedles;

providing a coating substrate;

providing an aqueous formulation comprising at least one active pharmaceutical ingredient and at least one excipient, wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 50° or greater and 96° or less when measured under ambient conditions;

applying the aqueous formulation to the coating substrate;

bringing the aqueous formulation and the microneedles into contact with one another;

removing the microneedles from the aqueous formulation; and

allowing at least a portion of the aqueous formulation to evaporate.

6. The method according to claim 5 , wherein the aqueous formulation has a contact angle on a medical grade polymeric material of 65° or greater and 96° C. or less when measured under ambient conditions.

7. The method according to claim 1 , wherein the at least one active pharmaceutical ingredient is selected from vaccines, proteins, peptides, and polynucleotide sequences.

8. The method according to claim 1 , wherein the at least one excipient comprises a buffer selected from histidine, phosphate buffers, acetate buffers, citrate buffers, glycine buffers, ammonium acetate buffers, succinate buffers, pyrophosphate buffers, Tris acetate (TA) buffers, Tris buffers, saline solutions buffered with any of the above, or combinations thereof.

9. The method according to claim 1 , wherein the at least one excipient comprises sucrose, dextrins, dextrans, hyroxyethyl cellulose (HEC), polyvinyl pyrrolidone (PVP), polyethylene glycols, amino acids, polysorbate, human serum albumin, ethanol, sodium chloride, EDTA, saccharin sodium dehydrate, or combinations thereof.

10. The method according to claim 1 , wherein the active pharmaceutical ingredient is a vaccine and the aqueous formulation further comprises one or more adjuvants.

11. The method according to claim 1 , wherein the material comprising the microneedle array is selected from polycarbonate and liquid crystalline polymer.

12. The method according to claim 1 , wherein the coating substrate is at least a portion of a coating well.

13. The method according to claim 12 , wherein the coating well comprises a bottom surface and the microneedles contact the bottom surface of the coating well.

14. The method according to claim 1 , wherein the step of applying the aqueous formulation to the coating substrate comprises applying an excess of aqueous formulation to the coating substrate and adjusting the amount of aqueous formulation on the coating substrate.

15. The method according to claim 14 , wherein the step of adjusting the amount of aqueous formulation on the coating substrate comprises removing some aqueous formulation using an edge device.

16. The method according to claim 1 , wherein the step of bringing the aqueous formulation and the microneedles of the microneedle array into contact with one another is repeated at least once.

17. The method according to claim 1 , wherein the aqueous formulation has a surface tension that is from 40 and 55 dynes/cm when measured under ambient conditions.

Assignments (5)
SECURITY INTEREST Recorded Dec 14, 2022
From: KINDEVA DRUG DELIVERY L.P.
To: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT
Reel/Frame 062122/0618 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENT COLLATERAL RECORDED AT R/F 053586/0715 Recorded Dec 12, 2022
From: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT
To: KINDEVA DRUG DELIVERY L.P.
Reel/Frame 062115/0707 →
SECURITY INTEREST Recorded Aug 24, 2020
From: KINDEVA DRUG DELIVERY L.P.
To: MIDCAP FINANCIAL TRUST, AS ADMINISTRATIVE AGENT
Reel/Frame 053586/0715 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2020
From: 3M COMPANY; 3M INNOVATIVE PROPERTIES COMPANY
To: KINDEVA DRUG DELIVERY L.P.
Reel/Frame 052818/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2013
From: DETERMAN, AMY S.; JOHNSON, PETER R.; MOSEMAN, JOAN T.; WOLDT, RYAN T.; HANSEN, KRISTEN J.
To: 3M INNOVATIVE PROPERTIES COMPANY
Reel/Frame 029653/0403 →